Subsequent Events	6 Months Ended
Jun. 30, 2026
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events *Additional Transaction with Investors of Sarborg Limited* On July 30, 2026, the Company entered into a Securities Purchase Agreement with shareholders of Sarborg. The investors of Sarborg agreed to sell to the Company, and the Company agreed to acquire from the shareholders of Sarborg, an aggregate of 270 shares of Sarborg, representing approximately 4.76% of the outstanding shares of Sarborg. As consideration for the purchase, the Company has agreed to issue to the shareholders of Sarborg, in the aggregate: pre-funded warrants to purchase up to 12,131,770 shares of the Company’s Common Stock. The pre-funded warrants portion of the consideration transferred have an exercise price of $0.0001 per share, subject to adjustment as set forth therein and may not be exercised until such time as the Company obtains the requisite approval from its stockholders in accordance with applicable Nasdaq rules and requirements, including approval for the issuance of the pre-funded warrant shares upon exercise of the pre-funded warrants, as a whole and in the aggregate, in excess of 19.99% of the Common Stock or the voting power that was outstanding on the date of the Securities Purchase Agreement. *Variation Agreement with NJS Foresight Bio-Advisory* On July 30, 2026, the Company agreed to a variation of the previous agreement with NJS Foresight Bio-Advisory (“NJS”) to compensate NJS with an additional $0.1 million, payable with 33,582 shares of the Company’s Common Stock for services performed to date. All shares are fully vested, fully paid and nonassessable upon issuance. *Variation Agreement with Thesprogen* On July 30, 2026, the Company agreed to a variation of the previous agreement with Thesprogen to compensate Thesprogen with an additional $0.1 million, payable with 33,582 shares of the Company’s Common Stock for services performed to date. All shares are fully vested, fully paid and nonassessable upon issuance. *Amendment to Letter Agreement with Maxim Group LLC* On July 29, 2026, the Company and Maxim entered into an amendment to the original agreement dated February 6, 2026. The amendment updated the first sentence of section 3(b) of the original agreement which stated the Company will issue Maxim or its designees 13,000 shares of the Company’s Common Stock is replaced with the Company will issue Maxim or its designees 25,000 shares of the Company’s Common Stock. *Consulting Agreement with EX-ANIMO LTD* On July 24, 2026, the Company and EX ANIMO Ltd (“EX-ANIMO”) entered into a consulting agreement. The Company agreed to issue $0.1 million of the Company’s Common Stock, totaling 32,110 shares, in exchange for consulting services to be rendered. *Shares Issued for Legal Services* On July 30, 2026, the Company issued 31,373 shares of the Company’s Common Stock for to a legal service provider for services rendered during July 2026.

Subsequent Events

6 Months Ended

Jun. 30, 2026

18. Subsequent Events

Additional Transaction with Investors of Sarborg Limited

On July 30, 2026, the Company entered into a Securities Purchase Agreement with shareholders of Sarborg. The investors of Sarborg agreed to sell to the Company, and the Company agreed to acquire from the shareholders of Sarborg, an aggregate of 270 shares of Sarborg, representing approximately 4.76% of the outstanding shares of Sarborg.

As consideration for the purchase, the Company has agreed to issue to the shareholders of Sarborg, in the aggregate: pre-funded warrants to purchase up to 12,131,770 shares of the Company’s Common Stock.

The pre-funded warrants portion of the consideration transferred have an exercise price of $0.0001 per share, subject to adjustment as set forth therein and may not be exercised until such time as the Company obtains the requisite approval from its stockholders in accordance with applicable Nasdaq rules and requirements, including approval for the issuance of the pre-funded warrant shares upon exercise of the pre-funded warrants, as a whole and in the aggregate, in excess of 19.99% of the Common Stock or the voting power that was outstanding on the date of the Securities Purchase Agreement.

Variation Agreement with NJS Foresight Bio-Advisory

On July 30, 2026, the Company agreed to a variation of the previous agreement with NJS Foresight Bio-Advisory (“NJS”) to compensate NJS with an additional $0.1 million, payable with 33,582 shares of the Company’s Common Stock for services performed to date. All shares are fully vested, fully paid and nonassessable upon issuance.

Variation Agreement with Thesprogen

On July 30, 2026, the Company agreed to a variation of the previous agreement with Thesprogen to compensate Thesprogen with an additional $0.1 million, payable with 33,582 shares of the Company’s Common Stock for services performed to date. All shares are fully vested, fully paid and nonassessable upon issuance.

Amendment to Letter Agreement with Maxim Group LLC

On July 29, 2026, the Company and Maxim entered into an amendment to the original agreement dated February 6, 2026. The amendment updated the first sentence of section 3(b) of the original agreement which stated the Company will issue Maxim or its designees 13,000 shares of the Company’s Common Stock is replaced with the Company will issue Maxim or its designees 25,000 shares of the Company’s Common Stock.

Consulting Agreement with EX-ANIMO LTD

On July 24, 2026, the Company and EX ANIMO Ltd (“EX-ANIMO”) entered into a consulting agreement. The Company agreed to issue $0.1 million of the Company’s Common Stock, totaling 32,110 shares, in exchange for consulting services to be rendered.

Shares Issued for Legal Services

On July 30, 2026, the Company issued 31,373 shares of the Company’s Common Stock for to a legal service provider for services rendered during July 2026.